Guangzhou Fermion Technology Co. Ltd. has described non-receptor tyrosine-protein kinase TYK2 (JH2 domain) inhibitors reported to be useful for the treatment of allergy, autoimmune disease, cancer, dermatological disorders, dry eye, myelofibrosis, neurological disorders and transplant rejection, among others.